作者
Marc Scherlinger,Vivien Guillotin,Isabelle Douchet,Pierre Vacher,Andréa Boizard-Moracchini,Jean‐Philippe Guégan,Anne Garreau,Nathalie Merillon,Agathe Vermorel,Emmanuel Ribeiro,Irène Machelart,Estibaliz Lazaro,Lionel Couzi,P. Duffau,Thomas Barnetche,Jean‐Luc Pellegrin,Jean‐François Viallard,Maya Saleh,Thierry Schaeverbeke,Patrick Legembre,Marie‐Elise Truchetet,Hélène Dumortier,Cécile Contin‐Bordes,Vanja Sisirak,Christophe Richez,Patrick Blanco
摘要
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a loss of tolerance toward self-nucleic acids, autoantibody production, interferon expression and signaling, and a defect in the regulatory T (T reg ) cell compartment. In this work, we identified that platelets from patients with active SLE preferentially interacted with T reg cells via the P-selectin/P-selectin glycoprotein ligand-1 (PSGL-1) axis. Selectin interaction with PSGL-1 blocked the regulatory and suppressive properties of T reg cells and particularly follicular T reg cells by triggering Syk phosphorylation and an increase in intracytosolic calcium. Mechanistically, P-selectin engagement on T reg cells induced a down-regulation of the transforming growth factor–β axis, altering the phenotype of T reg cells and limiting their immunosuppressive responses. In patients with SLE, we found an up-regulation of P- and E-selectin both on microparticles and in their soluble forms that correlated with disease activity. Last, blocking P-selectin in a mouse model of SLE improved cardinal features of the disease, such as anti-dsDNA antibody concentrations and kidney pathology. Overall, our results identify a P-selectin–dependent pathway that is active in patients with SLE and validate it as a potential therapeutic avenue.